December 13, 2018 GETTY – ARCHIVE
MADRID, December 13 (WASK EUROPE) –
Approximately 60,000 people are diagnosed each year in Spain from digestive tumors, according to the president of the Summit Treatment Treatment Treatment Group (TTD), Enrique Aranda, at the XXVI International Symposium for Regeneration and Treatment of Summative Tumors.
At the event, which is celebrated until tomorrow in Valencia, the specialist has highlighted the importance of organizing these international meetings to "present and discuss the latest developments in prevention, diagnosis and treatment digestive tumors, as well as future lines and an investigation ", as the news in this field is particularly excellent, as this is the family of malign tumors more often in the western countries.
More than 450 national and international experts argue, in these days, the latest developments in immunotherapy, precise medicine and evolutionary adaptation of tumors, among others.
The most common of these tumors, in Spain, is colorectal cancer, with more than 34,000 new cases in 2017 (20,600 men and 13,700 women). I am followed by gastric cancer, with about 8,300 new cases per year, pancreatic cancer, with 6,760 annual and junior diagnosis, with 4,500 men in men and 1,600 in women. Esophageal cancer is less frequent, with approximately 2,200 cases per year, according to data from the TTD Group.
Although its cases are not the highest, pancreatic cancer causes deaths in two years above 95 percent, according to Symposium co-ordinators, Dr. María José Safont, Hospital Medical Oncology Service The University of Valencia, and Professor Andrés Cervantes, the University's Clinical Hospital Medical Oncology Service, Valencia, has been developing "timely, but inherent" in this tumor.
These include improving the quality of the surgery for patients with local and investigative diseases, retrospective chemotherapy for patients with surgery, cooperative chemotherapy for some patient groups and some developments in treatment with Distance metastasis that suggests an increasing improvement of survival
The main scientific novelties are those with colorectal cancer. In particular, co-ordinators ensures that "over the last two years," very relevant information derived from international studies with significant Spanish participation "has emerged, suggesting "It is possible to reduce the length of the assistant chemotherapy treatment between six and three. months in sub-groups of patients with colon cancer. "This means" reducing the number of toxic effects of long use of chemotherapy ", such as sensitive toxicity, diarrhea and mucositis.
In terms of developments in other tumors, local rectal cancer will analyze "accurate evaluation and selection of patients who can benefit from conservative treatment," according to the co-ordinators. Similarly, "the latest developments in hepatobiliary tumors and neuroendocrine will be reviewed in a multidisciplinary perspective," emphasizes Cervantes.
International papers include the attention of the teacher's research and Cancer Treatment Institute in Turin, Giulia Siravegna, on the widespread evolution of tumors. In his presentation, he will discuss what is happening when tumors grow or move after treatment with therapies referred to molecular targets.